TAS-115 is primarily investigated for its potential in cancer treatment, particularly as a multi-kinase inhibitor. It targets specific kinases involved in tumor growth and angiogenesis, making it a candidate for treating various types of cancers, including solid tumors. Its dual inhibition of MET and VEGFR2 pathways is particularly noteworthy, as these are critical in cancer cell proliferation and blood vessel formation. Clinical trials are ongoing to evaluate its efficacy and safety in patients, with a focus on its ability to overcome resistance to other therapies. Additionally, TAS-115 is being studied for its potential to reduce cancer-related cachexia, a condition characterized by severe weight loss and muscle wasting, which significantly impacts patient quality of life.